Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Bluebird bio's blood disorder therapy effective - FDA staff

Published 06/07/2022, 09:22 AM
Updated 06/07/2022, 11:22 AM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

By Mrinalika Roy

(Reuters) - Bluebird bio's blood disorder treatment demonstrates "clinically meaningful" benefit in patients, staff reviewers at the U.S. Food and Drug Administration said in briefing documents published on Tuesday.

The company has applied for approval of beti-cel as a one-time gene therapy for the treatment of Beta-thalassemia patients dependent on blood transfusions.

Data provided supports the effectiveness of beti-cel in these patients, the staff said https://www.fda.gov/media/159009/download, sending the company's shares up 12% to $3.34. Through Monday's close, the stock has slumped about 70% this year following regulatory setbacks.

The reviewers also published documents https://www.fda.gov/media/159010/download for bluebird's other gene therapy, eli-cel, for treating a rare neurological disease called cerebral adrenoleukodystrophy in patients below 18 years, raising safety concerns.

It is unclear whether the treatment's benefit outweighs the significant and unknown long-term risk of myelodysplastic syndrome (MDS), the reviewers wrote. The agency put the program on clinical hold last year after three trial patients developed MDS, a type of cancer.

There was a causal relationship between the treatment and two of the cases, the reviewers said on Tuesday, adding longer follow-up will uncover additional cases.

In response, bluebird said totality of the data made a clear case for eli-cel's efficacy.

A panel of FDA's outside experts is scheduled to discuss approval of the treatments later this week.

It will mark a defining moment for gene therapy for it would be the first time the Cellular, Tissue, and Gene Therapies Advisory Committee has met since 2017. The panel had then recommended approval of the first U.S. gene therapy - Spark Therapeutics' Luxturna.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

The meeting's outcome is also seen as critical for bluebird after the company in March flagged "going concern" doubts.

"The company is in a very precarious financial position now, given cash runway...(the decision) is not only big for the gene therapy space, but pivotal for the company as well," William Blair analyst Raju Prasad told Reuters.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.